Elevation Oncology has tapped Lonza’s Synaffix to support the expansion of its pipeline, agreeing to pay up to $368 million ...

Corcept Therapeutics’ selective cortisol modulator failed to slow the progress of amyotrophic lateral sclerosis (ALS) in a ...

Keros Therapeutics has halted dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial ...

Pleno plans to launch its Raptor benchtop analyzer early next year, and it's poached Illumina's Vik Vaz to lead its ...

Though M&A deal value and volume both declined in biopharma in 2024 compared to the year prior, PwC analysts still believe ...

Hepion Pharmaceuticals and Pharma Two B have terminated a reverse merger agreement that was expected to close by the end of ...

The U.S. Preventive Services Task Force pitched an update to its guidelines for cervical cancer screening, endorsing HPV ...

Danish pharma company Bavarian Nordic is shutting down its U.S.-based R&D site in San Diego and laying off all 48 employees ...

It looks like Eli Lilly’s oral selective estrogen receptor degrader (SERD) imlunestrant may need some extra help to reach a ...

Cardiff Oncology’s investigational PLK1 inhibitor paired with standard-of-care treatment showed a 64% overall response rate ...

AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...

Q32 Bio still sees potential for its anti-IL-7R antibody as an alopecia treatment despite failing a phase 2 eczema study—but ...